Recent progress of diagnosis of malignant phaeochromocytoma

Xu Zhong,Weiqing Wang

DOI: https://doi.org/10.3760/cma.j.issn.1000-6699.2014.06.023

2014-01-01

Abstract:Currently,the diagnosis of malignant pheochromocytoma still faces a big challenge.Neither biochemical nor histological features can be reliably used to distinguish malignancy from benign tumors.Numerous efforts have been applied to identify novel molecular markers to predict malignancy.

What problem does this paper attempt to address?

Development Of Differential Diagnosis For Benign And Malignant Pheochromocytomas

Baohua Gao,Fanshan Kong,Zhishun Xu

DOI: https://doi.org/10.1111/j.1442-2042.2008.02111.x

2008-01-01

International Journal of Urology

Abstract:Unlike common malignant tumors, malignant pheochromocytomas cannot be definitely diagnosed using histological features. This unique nature of pheochromocytomas provides a valuable model that may promote the investigation of the mechanism of other common malignant tumors where similar frameworks are not available. Studies on malignant pheochromocytomas should benefit not only the individuals with pheochromocytomas but those with other tumors. A review on the development of differentiating diagnosis between malignant and benign pheochromocytomas in imaging studies, biological fluid examinations, pathological examinations, molecular markers and genome studies, was updated in the hopes of guiding the next studies of pheochromcytomas.
Research Progerss on Molecular Biochemistry of the Differenciation of Benign and Malignant Pheochromocytoma

MENG Jin,NING Guang

DOI: https://doi.org/10.3760/cma.j.issn.1673-4386.2009.01.016

2009-01-01

International Journal of Genetics

Abstract:The prevalence of malignant pheochromocytoma is about 10%,and is somewhat higher for paraganglioma.Classification of malignancy based on clinical presentation or histology has been of limited value.Progress has been made within the area of molecular biochemistry techniques for the differentiation of malignant and benign pheochromocytomas.Malignant and/or extra-adrenal pheochromocytomas are strongly associated with SDHB mutation.Other gene and molecular markers could be used as a prognostic multi-marker.The present review addresses on the advances of the research on molecular biochemistry study of the differentiation of benign and malignant pheochromoeytoma and paraganglioma.
Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients.

Feng,Yu Zhu,XiaoJing Wang,YuXuan Wu,WenLong Zhou,XiaoLong Jin,RongMing Zhang,FuKang Sun,Zacharia Kasoma,ZhouJun Shen

DOI: https://doi.org/10.1016/j.juro.2010.12.050

IF: 7.6

2011-01-01

The Journal of Urology

Abstract:PURPOSE:We evaluated the clinical characteristic, tumor feature and immunohistochemistry factors predicting malignant pheochromocytoma.MATERIALS AND METHODS:Between January 1999 and December 2008 we retrospectively reviewed the records of 136 patients with pheochromocytoma at Ruijin Hospital. We compared clinical characteristics (age, gender, symptoms and biochemical analysis), tumor features (site, weight and diameter) and the expression of 3 angiogenesis/metastasis related genes (VEGF, Cox-2 and MVD) by immunohistochemical analysis of benign vs malignant pheochromocytomas.RESULTS:Of the 136 patients 105 (77%) had benign and 31 (23%) had malignant pheochromocytoma. Malignant tumors were larger and heavier than benign tumors, and accompanied by higher plasma metanephrine secretion (each p <0.001). Mean tumor catecholamine and preoperative 24-hour urinary metanephrine or normetanephrine were obviously higher in malignant than in benign tumors (p <0.001). Also, 25 malignant tumors (81%) were immunopositive for VEGF while only 24 benign tumors (23%) showed this characteristic (p <0.001). Microvessel density and the rate of positive staining for Cox-2 protein in malignant samples were higher than in benign samples (p <0.001).CONCLUSIONS:Several promising predictive parameters are currently available to distinguish benign from malignant pheochromocytoma. Large (5 cm or greater) or heavy (250 gm or greater) tumors, multifocal and extra-adrenal tumors, early onset postoperative hypertension and higher plasma or urine metadrenaline are high risk factors predictive of malignant pheochromocytoma. Also, expression of the 3 angiogenesis or metastasis related genes VEGF, Cox-2 and MVD helps determine the diagnosis of malignancy and suggests strict followup.
[Malignant Pheochromocytoma: Diagnosis and Treatment].

D Yang,S Li,X Li,S Liu,H Wang,W Han,J Hao

1999-01-01

Abstract:OBJECTIVE:To review the experience with the diagnosis and treatment of malignant pheochromocytoma.METHODS:Between 1986 and 1996, 7 patients with malignant pheochromocytoma were analysed.RESULTS:Compared with benign pheochromocytoma of adrenal gland, the malignant one usually exceeded 7.0 cm in diameter, irregular in shape, invading the surrounding tissue and the normal structure of the effected adrenal gland disappeared. Bleeding and necrotic area were seen in tumor mass, even seemed as a cystic lesion with thick wall. In some patients, blood catecholamine and urine VMA significantly elevated without hypertension. The separating phenomenon and progressive weight loss, accelerated ESR were characteristics of malignant pheochromocytoma.CONCLUSIONS:In some patients with malignant pheochromocytoma, histological findings are not consistent with their biological behaviors. Follow-up studies is mandatory in malignant pheochromocytoma as well as in benign one. Recurrence and/or metastasis after operation often occur in patients with malignant pheochromocytoma. In addition to early diagnosis and surgery, radiotherapy of tumor bed and systematic chemotherapy should be emphasized.
Diagnosis of malignant chromaffin-cell tumor

Yi-ran JIANG,Wei-qing WANG

DOI: https://doi.org/10.3760/cma.j.issn.1673-4157.2009.01.013

2009-01-01

International Journal of Endocrinology and Metabolism

Abstract:Chromaffin-cell tumors are composed of pheochromocytomas and paragangliomas. The malignant pheochromocytomas accounting for about 10% of all pheochromocytomas. The prevalence of malignancy among paragangliomas is higher. Clinical, biochemical and histological features cannot reliably distinguish malignancy from benign tumors. Several imaging modalities have been utilized for the diagnosis and staging of these tumors. Gene expression profiling is conducted to identify a gene signature which could discriminate benign pheochromocytoma and paraganglioma from malignant ones.
The Expression and Significance of Tumor Marker in Malignant Pheochromocytoma

钱立新,邵鹏飞,吴宏飞,徐正铨,张炜,张伟明,华立新

DOI: https://doi.org/10.3760/j.issn:1001-9030.2005.12.047

2005-01-01

Abstract:Objective To study the effect of the factors for the diagnosis of the malignant pheochromocytoma including the vascular endothelial growth factor ( VEGF), proliferating cell nuclear antigen(PCNA), neuron-specific enolase (NSE) and telomerase, which have close relationship with the mechanism of the origin and development of the carcinoma. Methods The tissue of the tumor was embedded with the paraffin after the operation with 21 cases of benign tumor, 19 cases of malignant tumor and 14 cases of normal adrenal medulla. The intensity and area of the expression for VEGF, PCNA, NSE and telomerase in the section was studied by immunohistochemical staining in different tissue including benign tissue, malignant tissue and normal adrenal medually.The result of the staining was judged under the microscope. Results The positive rate of staining for VEGF is 14. 3 % , 38.1 % and 78. 9 % in the section of normal, benign and malignant tissue, respectively. The positive rate for VEGF in malignant is significant higher than benign tissue (P 0.01). The positive rate of staining for PCNA is 73.7% in malignant tissue,significantly higher than normal tissue 21.4% and benign tissue 33.3% ( P 0.05 ) . The positive rate of staining for NSE and telomerase has no significant difference between benign and malignant peochromocytoma. Conclusion The expression of VEGF and PCNA has significant difference in the tissue of malignant and benign pheochromocytoma, which contributes to the diagnosis of malignant pheochromocytoma. The morphology changes involved in the origin and development of the tumor was consistent with the clinical data of the patients. Studying the expression of NSE and telomerase by immunohistochemical staining has no significance for diagnosis of malignant pheochromocytoma.
Multi-disciplinary diagnosis and treatment of a malignant pheochromocytoma with multiple metastases

Yawen ZHENG,Xinwei ZHANG,Zhongli ZHAN,Zhaoxiang YE,Wengui XU,Peiguo WANG,Zhi GUO,Xin YAO,Guangru XIE,Dingzhi HUANG,Xiubao REN

DOI: https://doi.org/10.3969/j.issn.1000-8179.20131397

2013-01-01

Chinese Journal of Clinical Oncology

Abstract:Malignant pheochromocytomas are rare tumors that arise from chromaffin tissue,and the diagnostic criterion of malignancy is based on the development of metastases.In the case a patient suffers the tumor with liver,lung and bone metastases.However,the test results of tumor markers,gastroscopy,chest and abdominal CT,and PET-CT examination are hard to make a definite diagnosis.The patient was finally diagnosed with malignant pheochromocytoma with liver,lung and bone metastases following the needle biopsy of liver and underwent the excision of a right adrenal pheochromocytoma.Therapeutic standard for the malignant pheochromocytomas is not available so far.It is reported that chemotherapeutic CVD regimen(cyclophosphamide,vincristine,and daecarbazine) and sunitinib may be effectual in the alike cases.The patient received two cycles of CVD and one cycle of sunitinib,nevertheless,slow progression of the disease remained after the treatment.The results of multi-disciplinary treatment have suggested that 131I-MIBG may just be a choice for this patient.
Diagnosis and Treatment for Malignant Pheochromocytom:a Report of 19 Cases

邵鹏飞,钱立新,吴宏飞,张炜,顾民,徐正铨,眭元庚

DOI: https://doi.org/10.3969/j.issn.1007-4368.2004.04.029

2004-01-01

Abstract:To improve the diagnosis and the treatment with malignant pheochromocytoma. Methods: Eighteen eases had the symptom of hypertension or abdomen pain, and one had no symptom. The positive rate of the urine catecholamine and VMA was 31. 6%, 63. 2% respectively. CT, MR revealed the most tumor retroperitoneal were ectopic or growing invasively. Results: All patients received the operation and twelve were excised the tumor fully. Seven were excised the tumor partially or cut out under the envelope. The patients that received radical resection of tumors were followed up 1 to 5 years with no recurrence. Conclusion: Diagnosis of malignant pheochromocytoma at early stage needs the data from clinic, operation and pathology. Radical resection of the tumor can achieve good effects.
Strategies on clinical diagnosis and treatment of pheochromocytoma

Wei-qing WANG

DOI: https://doi.org/10.3760/cma.j.issn.1673-4157.2010.04.001

2010-01-01

International Journal of Endocrinology and Metabolism

Abstract:Pheochromocytoma is a rare disease,which has resulted in the prevalence of 0.5%-1% among patients with hypertension. The malignant hypertension of pheochromocytoma can lead to heart failure, myocardial infarction,stroke and renal dysfunction,so the early diagnosis and treatment of pheochromotytoma is with extremely importance. Here makes a discussion on the clinical features, biochemical diagnosis, localization, management and genetic screening.
Diagnosis and Treatment of Malignant Pheochromocytoma: Report of 29 Cases

WANG Xian-jin,SHEN Zhou-jun,WU Yu-xuan,ZHOU Wen-long,ZHONG Shan,ZHU Yu,SUN Fu-,kang SHAO Yuan,ZHANG Cun-ming,ZHU Zhao-wei

DOI: https://doi.org/10.3969/j.issn.1009-8291.2011.06.026

2011-01-01

Abstract:Objective To review the experience on the diagnosis and treatment of malignant pheochromocytoma(MP).Methods The clinical data of 29 cases of MP from April 2003 to Jan.2011 were retrospectively analyzed.Hypertension was observed in 26 cases(89.7%).The positive rate of plasma-free MNs and 24-hour urine CA was 92.3%(24/26) and 86.2%(25/29) respectively.The accuracy rate of localization of B-Ultrasound,CT,MRI and 131I-MIBG was 86.2%(25/29),96.6%(28/29),88.9%(8/9) and 81.2%(18/22),and suspected malignancy was 24.1%(7/29),55.2%(16/29),44.4%(4/9) and 40.9%(9/22) respectively.One case underwent radiotherapy,27 cases open surgery and 1 case retroperitoneal laparoscopic surgery.Results Of the 29 cases,17 tumors were on the adrenal glands and 12 outside of the adrenal glands.13 cases were diagnosed as MP intraoperatively according to tumor features,including structural damage,invasive growth,lymph node metastasis and so on.23 cases were diagnosed as MP with pathological examination.24 patients were followed up for 4 months to 8 years,during which 11 cases had tumor recurrences and 9 cases underwent re-operation.The metastatic sites of tumor included lung(4 cases),liver(4 cases),bone(3 cases),local lymph node(4 cases),extensive lymph node(2 cases),and multiple organs(3 cases).4 cases died and the rest survived.Conclusions Pathological examination is difficult to distinguish benign and malignant pheochromocytoma,which should be combined with imaging examination,laboratory examination and intraoperative findings.Radical tumor resection is the preferred choice to prolong survival and re-operation is effective to recurrent cases.Long-term follow-up is significant for the ultimate diagnosis and timely treatment of suspected cases.
Recent progress in molecular classification of phaeochromocytoma and paraganglioma

Emma Boehm,Anthony J Gill,Roderick Clifton-Bligh,Richard W Tothill

DOI: https://doi.org/10.1016/j.beem.2024.101939

2024-09-07

Abstract:Phaeochromocytomas (PC) and paragangliomas (PG) are neural crest cancers with high heritability. Recent advances in molecular profiling, including multi-omics and single cell genomics has identified up to seven distinct molecular subtypes. These subtypes are defined by mutations involving hypoxia-inducible factors (HIFs), Krebs cycle, kinase and WNT signalling, but are also defined by chromaffin differentiation states. PCPG have a dominant proangiogenic microenvironment linked to HIF pathway activity and are generally considered "immune cold" tumours with a high number of macrophages. PCPG subtypes can indicate increased metastatic risk but secondary mutations in telomere maintenance genes TERT or ATRX are required to drive the metastatic phenotype. Molecular profiling can identify molecular therapeutic (e.g. RET and EPAS1) and radiopharmaceutical targets while also helping to support variant pathogenicity and familial risk. Molecular profiling and subtyping of PCPG therefore confers the possibility of nuanced prognostication and individual treatment stratification but this still requires large-scale prospective validation.
Tumor Markers in the Diagnosis and Treatment of Malignant Pheochromocytomas

王天歌,王卫庆

DOI: https://doi.org/10.3760/cma.j.issn.1000-6699.2009.05.037

2009-01-01

Abstract:HER2,VEGF,hTERT,HSP90 and Ki-67 are tumor markers closely related to pheochromocytomas.Gene amplification and protein overexpression of these markers may be associated with the malignancy of pheochromocytomas.Recent studies have revealed that patients with aggressive malignant pheochromocytomas may benefit by VEGF-targeted therapy with Sunitinib.Trastuzumab,Gamitrinibs and tumor marker-targeted gene therapy may also be a therapeutic choice for malignant pheochromocytomas.
Expression and significance of VEGF and NSE in benign and malignant pheochromocytoma

CHEN Xiang,LI Yong,CHEN F

DOI: https://doi.org/10.3870/j.issn.1674-4624.2010.02.008

2010-01-01

Abstract:Objective To explore the expression and significance of tumor makers(VEGF and NSE) in benign and malignant pheochromocytoma,and analyze the potential clinical value and pathological significance that could provid auxiliary basis to distinguish its benign and malignant. Methods The tumor tissue samples from 18 cases of benign tumor,16 cases of malignant tumor and 17 cases of normal adrenal medulla were embedded with the paraffin postoperatively.The intensity and area of the expression for VEGF and NSE were studied by immunohistochemical staining(SP) in three kinds of tissue.The results of the staining were judged under the microscope. Results ①The positive rate for VEGF in malignant was significant higher than that in benign tissue(P<0.01).There was not significant difference in the positive rate of staining for VEGF between benign and normal tissue(P>0.05).The strong positive rate for VEGF in malignant was significantly much higher than that in benign tissue(P<0.01).②There was not significant difference in the positive rate of staining for NSE between benign and malignant pheochromocytoma(P<0.05),and the expression of NSE in benign tissue was also higher than normal tissue(P<0.05).The strong positive rate for VEGF in malignant was higher than benign tissue(P<0.05).③ The co-positive rate of VEGF and NSE in malignant tissue was higher than benign tissue(P<0.01). Conclusions Clinically,the detection of VEGF and NSE may offer valuable basis to distinguish the benign and malignant pheochromocytoma.The co-detection of them may imrove further the sensitivity of this approach.
The current and upcoming era of radiomics in phaeochromocytoma and paraganglioma

Zbyněk Tüdös,Lucia Veverková,Jan Baxa,Igor Hartmann,Filip Čtvrtlík

DOI: https://doi.org/10.1016/j.beem.2024.101923

2024-08-23

Abstract:The topic of the diagnosis of phaeochromocytomas remains highly relevant because of advances in laboratory diagnostics, genetics, and therapeutic options and also the development of imaging methods. Computed tomography still represents an essential tool in clinical practice, especially in incidentally discovered adrenal masses; it allows morphological evaluation, including size, shape, necrosis, and unenhanced attenuation. More advanced post-processing tools to analyse digital images, such as texture analysis and radiomics, are currently being studied. Radiomic features utilise digital image pixels to calculate parameters and relations undetectable by the human eye. On the other hand, the amount of radiomic data requires massive computer capacity. Radiomics, together with machine learning and artificial intelligence in general, has the potential to improve not only the differential diagnosis but also the prediction of complications and therapy outcomes of phaeochromocytomas in the future. Currently, the potential of radiomics and machine learning does not match expectations and awaits its fulfilment.
Malignancy in pheochromocytomas

Kaisa Salmenkivi,Päivi Heikkilä,Caj Haglund,Johanna Arola

DOI: https://doi.org/10.1111/j.1600-0463.2004.apm1120901.x

Apmis

Abstract:A catecholamine-secreting tumor arising from the chromaffin cells of the sympathoadrenal system was first termed pheochromocytoma by Poll in 1905. The term refers to the dysky (pheo) color (chromo) of the cut surface of the tumor when exposed to dichromate. Pheochromocytomas most commonly arise from the adrenal medulla. Extraadrenally located pheochromocytomas are called paragangliomas, and arise from the paraganglion system. An adrenal pheochromocytoma is usually a rounded, gray-white, firm tumor 3 to 5 cm in diameter. When larger, they can adhere to adjacent structures, although still not metastasizing. Most pheochromocytomas are benign. However, approximately 10% of these tumors metastasize. It is almost impossible to differentiate a benign from a malignant tumor only by histological criteria. Classically only metastasized tumors are considered malignant for certain. Many attempts have been made to find markers that would predict the future behavior of an unmetastasized pheochromocytoma. In this overview of malignancy in pheochromocytomas, different steps of the tumorigenesis and several markers associated with them are discussed.
'Great Masquerader': a history of diagnosing pheochromocytoma

Roneil Parikh,Jason Diab,Ronald Guevara,Hamish Russell,Peter Campbell

DOI: https://doi.org/10.1111/ans.19257

IF: 1.7

2024-10-27

ANZ Journal of Surgery

Abstract:This paper describes the timeline of important events and key discoveries over more than a century that have contributed to the advancement and evolution of diagnosis of pheochromocytoma and the improved understanding of its behaviour and associations today. Introduction Pheochromocytoma is a unique tumour with a variety of clinical presentations. Coined as 'the great masquerader', it can present with the classical triad of headache, sweating and tachycardia and sometimes in an acute hypertensive crisis. This paper describes the evolutionary history of the diagnosis of this condition. Methods A literature review was conducted using Medline Database from 1900 to 2023 outlining the methods of diagnosis for pheochromocytoma. Results There have been diagnostic dilemmas and localization challenges of pheochromocytoma over the last century. From the first description of pheochromocytoma in 1886 to the first successful resection in 1926, there was poor recognition of its atypical symptoms and lack of reliable diagnostic tests. Over the next few decades, there were significant advances in screening and biochemical tests. Further understanding of catecholamine release and metabolic pathways led to the development of tests to identify end products of catecholamine metabolism in plasma and urine. Computed imaging however heralded significant improvement in surgical planning and management. The evolution of histopathological diagnosis with the use of immunostains and genetic testing has further contributed to the identification of malignant pheochromocytomas and an understanding of their behaviours. Conclusion Significant advances in the biochemical and imaging have shaped our understanding of pathophysiology and management. These diagnostic advances have enabled early and accurate detection and localization of pheochromocytomas to enable prompt surgical management.

surgery
Current Progress of Diagnostic and Prognostic Markers in Gliomas

Yan-wu Yang,Qing Mao

2012-01-01

Abstract:Glioma is the most common malignant tumor in the central nervous system.The particularity of its position makes it difficult for diagnosis.As a result,looking for glioma biomarkers is important for diagnosis and prediction of the prognosis.With the application of new technology of molecular biology,series of biological markers have been found.This review summarized recent studies on diagnostic and prognostic markers for gliomas such as the BRAF fusion gene in pilocytic astrocytomas and 1p/19q codeletion,O-6-methylguanine-DNA methyltransferase status and isocitrate dehydrogenase gene mutations in diffuse gliomas.These glioma biomarkers have been expected to facilitate diagnosis and the prediction of patient outcome.
Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.

Xu Zhong,Lei Ye,TingWei Su,Jing Xie,Weiwei Zhou,Yiran Jiang,Lei Jiang,Guang Ning,Weiqing Wang

DOI: https://doi.org/10.1111/cen.13357

2017-01-01

Clinical Endocrinology

Abstract:ObjectiveNo single histological or molecular marker is diagnostic for malignant phaeochromocytomas and paragangliomas (PPGLs). This study aimed to establish and evaluate a prognostic nomogram to improve the prediction of metastatic probability in individual PPGL patients. MethodsThree hundred and 47 consecutive PPGL patients from January 2002 through December 2014 were randomly divided into a training set (n=208) and a validation set (n=139). A multivariate logistic regression analysis of selected prognostic features was performed, and a nomogram to predict metastasis was constructed. Discrimination and calibration were employed to evaluate the performance of the nomogram. Clinical usefulness was calculated using decision curve analysis. ResultsThe overall metastatic rate was 10.6%. Primary tumour size, primary tumour location, vascular invasion, ERBB-2 overexpression, SDHB mutation and catecholamine type were associated with malignancy in the logistic analysis and were included in the nomogram. The nomogram showed an area under the receiver operating characteristic curve (AUC) of 0.872 (95% confidence interval [CI], 0.819-0.914) in the training set. The validation set showed good discrimination, with an AUC of 0.870 (95% CI, 0.803-0.921). The nomogram was well calibrated, with no significant difference between the predicted and the observed probabilities (Hosmer-Lemeshow test: P=.510 for the training set; .314 for the validation set). Decision curve analysis revealed that molecular markers (ERBB-2 overexpression and SDHB mutation) could increase the clinical benefit of the nomogram. ConclusionOur results support the use of the present biomarker-based nomogram, which has good discriminative ability, to predict the metastatic probability of PPGLs.
Expression and Correlation of Heparanase-1 and Vascular Endothelial Growth Factor in Pheochromocytomas

祝宇,沈周俊,吴瑜璇,袁菲,张俊,芮文斌,张翀宇,计骏,赵菊平,孙福康,周文龙,谢欣,金晓龙,宁光

DOI: https://doi.org/10.3969/j.issn.1009-8291.2009.02.002

2009-01-01

Abstract:Objective To detect the expression of Heparanase-1(HPA)and vascular endothelial growth factor(VEGF)in benign and malignant pheochromocytomas,to analyse the value of HPA and VEGF as marker for malignant pheochromocytomas,and to investigate the relationship between HPA and VEGF.Methods Tissue specimens were obtained in operations performed in Ruijin Hospital from 1986～2006.There were 38 pheochromocytomas(including 21 benign and 17 malignant)and the clinical and pathological data were available.The malignant groups follow-up ranged from 28 to 179 months.The benign groups follow-up ranged from 93 to 264 months.Normal adrenal glands were from 20 patients undergoing nephrectomy for benign renal tumor.Immunohistochemical technology was performed to detect the HPA and VEGF in all patients.Results Strong HPA expression was found in malignant pheochromocytomas(76.47%),whereas weak expression in benign pheochromocytomas(28.57%)and no expression in normal adrenal medulla immunohistochemically.There was statistical difference between malignant and benign groups,and between malignant group and normal adrenal medulla group(P0.05).Strong VEGF expression was found in malignant pheochromocytomas(82.40%),whereas weak expression in benign pheochromocytomas(23.80%)and in normal adrenal medulla(5.00%)respectively.There was statistical difference between malignant and benign group,also between malignant group and normal adrenal medulla group(P0.05).There was positive relationship between HPA and VEGF in pheochromocytomas.Conclusion HPA and VEGF may become the predictor markers for malignant pheochromocytoma.
Diagnosis and Surgical Management of Adrenal Gland Pheochromocytoma

于新路,王禾,张波,秦卫军

DOI: https://doi.org/10.3321/j.issn:1000-2790.2003.07.034

2003-01-01

Journal of Clinical Urology

Abstract:Purpose:To study and evaluate the diagnosis and treatment strategy of pheochromocytoma.Methods:109 Cases of pheochromocytoma diagnosed and treated between 1976 and 2001 were reviewed and studied:There were 104 cases with high blood catecholamine. Urinary Vanilly1 mandelic acid (VMA) was the best marker with a positive sensitivity rate of 90.8 %. The accurate localization rate of the tumors was 89.0 % for B ultrasohography, 92.7 % for CT and 100% for MRI.Results:Radical adrenalectomy was carried out for 106 cases and there were 3 cases with laparoscopic adrenalectomy. Operative therapy was successful in all cases. The diagnosis of all cases was confirmed by pathologic studies.102 cases ( 93.6 %) were benign and other 7 cases ( 6.4 % ) were malignant.Conclusions:The procedures of the qualitative and locative diagnosis of adrenal gland pheochromocytoma included clinical manifestations, urinary VMA assessment and imaging investigation. Surgical management was the only means for cure and preoperative preparation was extremely important. Laparoscopic adrenalectomy was safe and effective for managing adrenal gland pheochromocytoma.

Recent progress of diagnosis of malignant phaeochromocytoma

Development Of Differential Diagnosis For Benign And Malignant Pheochromocytomas

Research Progerss on Molecular Biochemistry of the Differenciation of Benign and Malignant Pheochromocytoma

Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients.

[Malignant Pheochromocytoma: Diagnosis and Treatment].

Diagnosis of malignant chromaffin-cell tumor

The Expression and Significance of Tumor Marker in Malignant Pheochromocytoma

Multi-disciplinary diagnosis and treatment of a malignant pheochromocytoma with multiple metastases

Diagnosis and Treatment for Malignant Pheochromocytom:a Report of 19 Cases

Strategies on clinical diagnosis and treatment of pheochromocytoma

Diagnosis and Treatment of Malignant Pheochromocytoma: Report of 29 Cases

Recent progress in molecular classification of phaeochromocytoma and paraganglioma

Tumor Markers in the Diagnosis and Treatment of Malignant Pheochromocytomas

Expression and significance of VEGF and NSE in benign and malignant pheochromocytoma

The current and upcoming era of radiomics in phaeochromocytoma and paraganglioma

Malignancy in pheochromocytomas

'Great Masquerader': a history of diagnosing pheochromocytoma

Current Progress of Diagnostic and Prognostic Markers in Gliomas

Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.

Expression and Correlation of Heparanase-1 and Vascular Endothelial Growth Factor in Pheochromocytomas

Diagnosis and Surgical Management of Adrenal Gland Pheochromocytoma